Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.

Clinical lung cancer - 1 Jan 2022

Li Yalun, Wang Ke, Tian Panwen, Li Weimin

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung
Share to Crizotinib
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Oncogene Proteins, Fusion

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 34802880
DOI: 10.1016/j.cllc.2021.10.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.PMID 34802880Read ↗

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.Semantic proximity Read ↗

A rapid and durable response to cabozantinib in an osimertinib- resistant lung cancer patient with MET D1228N mutation: a case reportSemantic proximity Read ↗

Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.Semantic proximity Read ↗

Crizotinib plus erlotinib overcomes osimertinib resistance in a seriously-ill non-small cell lung cancer patient with acquired MET amplification.Semantic proximity Read ↗

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.Semantic proximity Read ↗

An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.Semantic proximity Read ↗

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.Semantic proximity Read ↗

Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism.Semantic proximity Read ↗

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.Semantic proximity Read ↗

Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review.Semantic proximity Read ↗

Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.